Follow-On Biologics Bill Clears Senate Cmte. With Stronger Language On Exclusivity Cap
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firms remain concerned that innovators would be able to "evergreen" their products through minor changes.
You may also be interested in...
Follow-On Biologics Legislation Could Reach Senate Floor By Year End
Design of patent protection, exclusivity and interchangeability provisions remains potential roadblock.
Follow-On Biologics Legislation Could Reach Senate Floor By Year End
Design of patent protection, exclusivity and interchangeability provisions remains potential roadblock.
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19